Events & Presentations

Corporate Presentation

AiCuris presents novel data on its candidate AIC468, an antisense oligonucleotide for treatment of BKV infections

Our team has been making waves at the 34th ESCMID Global in Barcelona and the ATC2024 in Philadelphia with lively discussions around impressive AIC468 data at the respective poster sessions.

AIC468 is a first-in-class antiviral antisense oligonucleotide in clinical development for the treatment of BKV infection in kidney transplant recipients. If you are interested to learn more about this promising program, you can download the presented posters here.

AiCuris Senior Management heading to San Francisco for the J.P. Morgan Annual Healthcare Conference from January 8th–11th

Meet with our CEO Larry Edwards and CFO Sabrina Kuttruff-Coqui at the J.P. Morgan Annual Healthcare Conference.

With Senior Management from both our German headquarters and US subsidiary joining, we are looking forward to starting off the new year 2024 with an inspirational week of meetings and the opportunity to connect to stakeholders of the biotech industry. If you are interested in discussing novel antiviral therapy options for patients with a weakened immune system, as well as exciting business opportunities, ask for a meeting via info@aicuris.com.